HC Wainwright Has Strong Estimate for ALLO FY2025 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a report released on Monday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.93) for the year, up from their previous forecast of ($1.06). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q4 2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($1.01) EPS.

Several other brokerages have also commented on ALLO. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Wall Street Zen cut shares of Allogene Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Allogene Therapeutics in a report on Wednesday, October 8th. Finally, JMP Securities reiterated a “market perform” rating on shares of Allogene Therapeutics in a research report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.44.

Allogene Therapeutics Stock Up 5.1%

Allogene Therapeutics stock opened at $1.24 on Wednesday. The business has a 50-day simple moving average of $1.22 and a 200 day simple moving average of $1.23. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $3.78. The stock has a market cap of $278.67 million, a price-to-earnings ratio of -1.27 and a beta of 0.42.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04.

Insiders Place Their Bets

In other Allogene Therapeutics news, CFO Geoffrey M. Parker sold 36,744 shares of the company’s stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $1.26, for a total transaction of $46,297.44. Following the completion of the sale, the chief financial officer directly owned 1,276,796 shares in the company, valued at $1,608,762.96. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 13.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Allogene Therapeutics

Several institutional investors have recently bought and sold shares of ALLO. Savant Capital LLC purchased a new position in Allogene Therapeutics in the 3rd quarter worth approximately $27,000. Brighton Jones LLC increased its position in shares of Allogene Therapeutics by 81.6% during the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock valued at $31,000 after buying an additional 11,311 shares during the period. CANADA LIFE ASSURANCE Co raised its position in shares of Allogene Therapeutics by 142.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock worth $35,000 after acquiring an additional 18,314 shares in the last quarter. R Squared Ltd bought a new position in Allogene Therapeutics in the second quarter worth $37,000. Finally, Engineers Gate Manager LP bought a new position in shares of Allogene Therapeutics in the 2nd quarter worth about $37,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).